NASDAQ:LNAI

Lunai Bioworks Q3 2026 Earnings Report

Lunai Bioworks logo
$3.56 +0.13 (+3.79%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$3.36 -0.20 (-5.62%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lunai Bioworks EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lunai Bioworks Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lunai Bioworks Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lunai Bioworks Earnings Headlines

SpaceX Opens Up 11% — Here’s What You Need to Know
SpaceX - ticker SPCX - just completed the biggest IPO in American history, raising $75 billion at a $1.8 trillion valuation. Goldman Sachs projects $474 billion in revenue by 2030, while Morgan Stanley goes further - $3.4 trillion by 2040. But NYU's Aswath Damodaran, Wall Street's 'Dean of Valuation,' called those projections 'a hallucination.' While every camera pointed at the rockets, Musk quietly placed a major bet on what he calls 'the world's biggest product' - something he believes could generate $30 trillion in revenue. Sixty of America's largest companies are making the same move, and the signal appeared in a quiet Friday SEC filing almost nobody noticed.tc pixel
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
See More Lunai Bioworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lunai Bioworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lunai Bioworks and other key companies, straight to your email.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

View Lunai Bioworks Profile